(CercleFinance.com) – Mercedes-Benz Vans announces that despite continuous fluctuations in the field of semiconductor supply, sales remained practically at the level of the previous year in the second quarter of 2022 with 100,000 units in total worldwide (-2%).
The manufacturer says it sold 3,900 battery electric vans during the second quarter (April to June), a figure up 61%.
The share of purely electric eSprinter and eVito nearly doubled to around 3,100 units (+97%). However, in the midsize van segment destined for the private sector, deliveries of the EQV fell 4% from April to June.
From April to June, 83,900 commercial vans of the (e)Sprinter, (e)Vito, (e)Vito Tourer and Citan models were handed over to customers (-0%). In the United States, sales of Sprinter and Metris (Vito) vans almost doubled to 19,700 units (+96%), representing record sales in one quarter.
The strong portfolio of Mercedes-Benz Vans also convinces in the private segment. In addition to the V-Class and the EQV, the new T-Class (T2 2022: 300 units) was handed over to customers for the first time. In total, 16,000 private vans were sold (-10%). The continued motorhome boom continues to have a positive impact on demand for the Marco Polo and all its derivatives.
Bayer today announced that new data from its radiology portfolio will be presented at the European Congress of Radiology (ECR), taking place July 13-17 in Vienna, Austria.
In particular, the laboratory will present its preclinical data on the new development compound gadoquatrane, which is currently in phase II development.
Gadoquatrane exhibits high stability as well as high relaxivity – a key property for use in contrast-enhanced magnetic resonance imaging (MRI) – with the potential to allow for a significantly lower gadolinium (Gd) dose.
Another focus is on clinical data on Bayer Gadovist’s MRI contrast agent (gadobutrol), investigating the clinical effectiveness of a reduced dose of gadobutrol compared to a standard dose of gadoterate in patients undergoing MRI of the contrast-enhanced central nervous system (CNS).
Bayer will also present its research exploring the potential of deep learning to optimize the delivery of contrast media. “AI can help manage the growing workload of radiologists and their teams, ultimately striving to improve patient care,” the lab says.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
